Helicobacter pylori infection and gastric cancer

Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-med...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Baillière's best practice & research. Clinical gastroenterology 2007-01, Vol.21 (2), p.281-297
Hauptverfasser: Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK), El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 297
container_issue 2
container_start_page 281
container_title Baillière's best practice & research. Clinical gastroenterology
container_volume 21
creator Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)
El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)
description Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-mediated cancer. In this paper, we discuss the evidence for the association between H. pylori and gastric adenocarcinoma and MALT lymphoma. We also discuss the pathogenesis of these two forms of cancer and the factors that determine their outcome. There is no doubt that the knowledge accumulated over the past two decades will be translated into eventual victory over this killer cancer, largely because we now appreciate that the best way to prevent the cancer is by preventing acquisition of the infection in the first place, or by eradicating the infection in infected subjects. Defining the optimal timing of intervention is going to be the challenge facing us over the next two decades.
doi_str_mv 10.1016/j.bpg.2007.02.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70310435</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521691807000133</els_id><sourcerecordid>2807408491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-51aa9a1e61f90e96f8866d21404a9f06bc556ef2f3c60f1d881866f9ffb819033</originalsourceid><addsrcrecordid>eNp9kUFr2zAYhsVYWbK2P2CXYRj0Zvf7JFu2GAxK6JpBoYduZyHLn4oyx84kp5B_X7kJFHrYSTo874v0vIx9QSgQUF5vinb3VHCAugBeAPAPbImV4DkqlB_nO8dcKmwW7HOMG4AUUuoTW2AtGs7reslgTb23Y2vsRCHbHfox-MwPjuzkxyEzQ5c9mTgFbzNrBkvhgp0500e6PJ3n7M_P29-rdX7_cPdrdXOf21KUU16hMcogSXQKSEnXNFJ2HEsojXIgW1tVkhx3wkpw2DUNJsAp59oGFQhxzq6Ovbsw_ttTnPTWR0t9bwYa91HXIBBKUSXw2ztwM-7DkN6mEQUojhJ4ovBI2TDGGMjpXfBbEw4aQc8y9UYnmXqWqYFreM18PTXv2y11b4mTvQR8PwKURDx7CjpaT8lS50MSqLvR_7f-x7u07f3gren_0oHi2y90TAH9OK85jwn1PKQQ4gWdv5cK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1130921602</pqid></control><display><type>article</type><title>Helicobacter pylori infection and gastric cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK) ; El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creator><creatorcontrib>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK) ; El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creatorcontrib><description>Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-mediated cancer. In this paper, we discuss the evidence for the association between H. pylori and gastric adenocarcinoma and MALT lymphoma. We also discuss the pathogenesis of these two forms of cancer and the factors that determine their outcome. There is no doubt that the knowledge accumulated over the past two decades will be translated into eventual victory over this killer cancer, largely because we now appreciate that the best way to prevent the cancer is by preventing acquisition of the infection in the first place, or by eradicating the infection in infected subjects. Defining the optimal timing of intervention is going to be the challenge facing us over the next two decades.</description><identifier>ISSN: 1521-6918</identifier><identifier>EISSN: 1532-1916</identifier><identifier>DOI: 10.1016/j.bpg.2007.02.002</identifier><identifier>PMID: 17382277</identifier><identifier>CODEN: BPRCB6</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adenocarcinoma - epidemiology ; Adenocarcinoma - etiology ; Adenocarcinoma - prevention &amp; control ; Animals ; Antibiotics ; Cancer ; chronic gastritis ; Confidence intervals ; cytokines ; Disease prevention ; Disease Progression ; Epidemiology ; gastric cancer ; Gastritis - epidemiology ; Gastritis - physiopathology ; Gastroenterology and Hepatology ; Helicobacter Infections - epidemiology ; Helicobacter Infections - etiology ; Helicobacter Infections - physiopathology ; Helicobacter Infections - therapy ; Helicobacter pylori ; Helicobacter pylori - pathogenicity ; host genetic factors ; Humans ; Infections ; Lymphoma, B-Cell, Marginal Zone - epidemiology ; Lymphoma, B-Cell, Marginal Zone - etiology ; Lymphoma, B-Cell, Marginal Zone - physiopathology ; MALT lymphoma ; Meta-analysis ; Pathogenesis ; Polymorphism, Genetic ; polymorphisms ; Risk Factors ; Stomach Neoplasms - microbiology ; Stomach Neoplasms - prevention &amp; control ; Studies ; Therapy ; Ulcers ; Virulence</subject><ispartof>Baillière's best practice &amp; research. Clinical gastroenterology, 2007-01, Vol.21 (2), p.281-297</ispartof><rights>Elsevier Ltd</rights><rights>2007 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-51aa9a1e61f90e96f8866d21404a9f06bc556ef2f3c60f1d881866f9ffb819033</citedby><cites>FETCH-LOGICAL-c434t-51aa9a1e61f90e96f8866d21404a9f06bc556ef2f3c60f1d881866f9ffb819033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bpg.2007.02.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17382277$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)</creatorcontrib><creatorcontrib>El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creatorcontrib><title>Helicobacter pylori infection and gastric cancer</title><title>Baillière's best practice &amp; research. Clinical gastroenterology</title><addtitle>Best Pract Res Clin Gastroenterol</addtitle><description>Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-mediated cancer. In this paper, we discuss the evidence for the association between H. pylori and gastric adenocarcinoma and MALT lymphoma. We also discuss the pathogenesis of these two forms of cancer and the factors that determine their outcome. There is no doubt that the knowledge accumulated over the past two decades will be translated into eventual victory over this killer cancer, largely because we now appreciate that the best way to prevent the cancer is by preventing acquisition of the infection in the first place, or by eradicating the infection in infected subjects. Defining the optimal timing of intervention is going to be the challenge facing us over the next two decades.</description><subject>Adenocarcinoma - epidemiology</subject><subject>Adenocarcinoma - etiology</subject><subject>Adenocarcinoma - prevention &amp; control</subject><subject>Animals</subject><subject>Antibiotics</subject><subject>Cancer</subject><subject>chronic gastritis</subject><subject>Confidence intervals</subject><subject>cytokines</subject><subject>Disease prevention</subject><subject>Disease Progression</subject><subject>Epidemiology</subject><subject>gastric cancer</subject><subject>Gastritis - epidemiology</subject><subject>Gastritis - physiopathology</subject><subject>Gastroenterology and Hepatology</subject><subject>Helicobacter Infections - epidemiology</subject><subject>Helicobacter Infections - etiology</subject><subject>Helicobacter Infections - physiopathology</subject><subject>Helicobacter Infections - therapy</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - pathogenicity</subject><subject>host genetic factors</subject><subject>Humans</subject><subject>Infections</subject><subject>Lymphoma, B-Cell, Marginal Zone - epidemiology</subject><subject>Lymphoma, B-Cell, Marginal Zone - etiology</subject><subject>Lymphoma, B-Cell, Marginal Zone - physiopathology</subject><subject>MALT lymphoma</subject><subject>Meta-analysis</subject><subject>Pathogenesis</subject><subject>Polymorphism, Genetic</subject><subject>polymorphisms</subject><subject>Risk Factors</subject><subject>Stomach Neoplasms - microbiology</subject><subject>Stomach Neoplasms - prevention &amp; control</subject><subject>Studies</subject><subject>Therapy</subject><subject>Ulcers</subject><subject>Virulence</subject><issn>1521-6918</issn><issn>1532-1916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFr2zAYhsVYWbK2P2CXYRj0Zvf7JFu2GAxK6JpBoYduZyHLn4oyx84kp5B_X7kJFHrYSTo874v0vIx9QSgQUF5vinb3VHCAugBeAPAPbImV4DkqlB_nO8dcKmwW7HOMG4AUUuoTW2AtGs7reslgTb23Y2vsRCHbHfox-MwPjuzkxyEzQ5c9mTgFbzNrBkvhgp0500e6PJ3n7M_P29-rdX7_cPdrdXOf21KUU16hMcogSXQKSEnXNFJ2HEsojXIgW1tVkhx3wkpw2DUNJsAp59oGFQhxzq6Ovbsw_ttTnPTWR0t9bwYa91HXIBBKUSXw2ztwM-7DkN6mEQUojhJ4ovBI2TDGGMjpXfBbEw4aQc8y9UYnmXqWqYFreM18PTXv2y11b4mTvQR8PwKURDx7CjpaT8lS50MSqLvR_7f-x7u07f3gren_0oHi2y90TAH9OK85jwn1PKQQ4gWdv5cK</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)</creator><creator>El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Helicobacter pylori infection and gastric cancer</title><author>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK) ; El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-51aa9a1e61f90e96f8866d21404a9f06bc556ef2f3c60f1d881866f9ffb819033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adenocarcinoma - epidemiology</topic><topic>Adenocarcinoma - etiology</topic><topic>Adenocarcinoma - prevention &amp; control</topic><topic>Animals</topic><topic>Antibiotics</topic><topic>Cancer</topic><topic>chronic gastritis</topic><topic>Confidence intervals</topic><topic>cytokines</topic><topic>Disease prevention</topic><topic>Disease Progression</topic><topic>Epidemiology</topic><topic>gastric cancer</topic><topic>Gastritis - epidemiology</topic><topic>Gastritis - physiopathology</topic><topic>Gastroenterology and Hepatology</topic><topic>Helicobacter Infections - epidemiology</topic><topic>Helicobacter Infections - etiology</topic><topic>Helicobacter Infections - physiopathology</topic><topic>Helicobacter Infections - therapy</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - pathogenicity</topic><topic>host genetic factors</topic><topic>Humans</topic><topic>Infections</topic><topic>Lymphoma, B-Cell, Marginal Zone - epidemiology</topic><topic>Lymphoma, B-Cell, Marginal Zone - etiology</topic><topic>Lymphoma, B-Cell, Marginal Zone - physiopathology</topic><topic>MALT lymphoma</topic><topic>Meta-analysis</topic><topic>Pathogenesis</topic><topic>Polymorphism, Genetic</topic><topic>polymorphisms</topic><topic>Risk Factors</topic><topic>Stomach Neoplasms - microbiology</topic><topic>Stomach Neoplasms - prevention &amp; control</topic><topic>Studies</topic><topic>Therapy</topic><topic>Ulcers</topic><topic>Virulence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)</creatorcontrib><creatorcontrib>El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Baillière's best practice &amp; research. Clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lochhead, Paul, BSc (Hons), MB CHB, MRCP (UK)</au><au>El-Omar, Emad M., BSc (Hons), MB ChB, MD, FRCP (Edin)</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Helicobacter pylori infection and gastric cancer</atitle><jtitle>Baillière's best practice &amp; research. Clinical gastroenterology</jtitle><addtitle>Best Pract Res Clin Gastroenterol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>21</volume><issue>2</issue><spage>281</spage><epage>297</epage><pages>281-297</pages><issn>1521-6918</issn><eissn>1532-1916</eissn><coden>BPRCB6</coden><abstract>Gastric cancer remains a major health burden on many societies claiming hundreds of thousands of lives every year. The discovery of Helicobacter pylori has no doubt revolutionised our understanding of this malignancy, which is now regarded as a paradigm for infection-induced chronic inflammation-mediated cancer. In this paper, we discuss the evidence for the association between H. pylori and gastric adenocarcinoma and MALT lymphoma. We also discuss the pathogenesis of these two forms of cancer and the factors that determine their outcome. There is no doubt that the knowledge accumulated over the past two decades will be translated into eventual victory over this killer cancer, largely because we now appreciate that the best way to prevent the cancer is by preventing acquisition of the infection in the first place, or by eradicating the infection in infected subjects. Defining the optimal timing of intervention is going to be the challenge facing us over the next two decades.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>17382277</pmid><doi>10.1016/j.bpg.2007.02.002</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1521-6918
ispartof Baillière's best practice & research. Clinical gastroenterology, 2007-01, Vol.21 (2), p.281-297
issn 1521-6918
1532-1916
language eng
recordid cdi_proquest_miscellaneous_70310435
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adenocarcinoma - epidemiology
Adenocarcinoma - etiology
Adenocarcinoma - prevention & control
Animals
Antibiotics
Cancer
chronic gastritis
Confidence intervals
cytokines
Disease prevention
Disease Progression
Epidemiology
gastric cancer
Gastritis - epidemiology
Gastritis - physiopathology
Gastroenterology and Hepatology
Helicobacter Infections - epidemiology
Helicobacter Infections - etiology
Helicobacter Infections - physiopathology
Helicobacter Infections - therapy
Helicobacter pylori
Helicobacter pylori - pathogenicity
host genetic factors
Humans
Infections
Lymphoma, B-Cell, Marginal Zone - epidemiology
Lymphoma, B-Cell, Marginal Zone - etiology
Lymphoma, B-Cell, Marginal Zone - physiopathology
MALT lymphoma
Meta-analysis
Pathogenesis
Polymorphism, Genetic
polymorphisms
Risk Factors
Stomach Neoplasms - microbiology
Stomach Neoplasms - prevention & control
Studies
Therapy
Ulcers
Virulence
title Helicobacter pylori infection and gastric cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A20%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Helicobacter%20pylori%20infection%20and%20gastric%20cancer&rft.jtitle=Bailli%C3%A8re's%20best%20practice%20&%20research.%20Clinical%20gastroenterology&rft.au=Lochhead,%20Paul,%20BSc%20(Hons),%20MB%20CHB,%20MRCP%20(UK)&rft.date=2007-01-01&rft.volume=21&rft.issue=2&rft.spage=281&rft.epage=297&rft.pages=281-297&rft.issn=1521-6918&rft.eissn=1532-1916&rft.coden=BPRCB6&rft_id=info:doi/10.1016/j.bpg.2007.02.002&rft_dat=%3Cproquest_cross%3E2807408491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1130921602&rft_id=info:pmid/17382277&rft_els_id=S1521691807000133&rfr_iscdi=true